RE: No rns ref phase 37 Dec 2020 08:51
The announcement follows positive Phase II SNG001 COVID-19 data that supports progression into a Phase III trial designed to be sufficient for marketing authorisation applications in 2021, with regulatory discussions on-going and manufacturing scale-up activity underway.
The gross proceeds of the Placing will be used to:
· fund a Phase III clinical trial of SNG001 in c. 900 COVID-19 patients across c. 20 countries, with an anticipated start date in Q4 2020;
· fund SNG001 manufacturing and device scale up activities, with the aim of producing c. 100,000 treatment courses per month in 2021;
· generate further data to support SNG001 clinical development, manufacturing processes and regulatory activities;